Novocure, Zai shares rally after lung-cancer treatment meets primary endpoint in study

Shares of Novocure Ltd.
NVCR,
+3.81%
soared 71.5% in premarket trading on Thursday after the company said the experimental non-small cell lung cancer treatment it’s developing with Zai Lab Ltd.
ZLAB,
+9.99%
met the primary endpoint in an open-label clinical trial, which assesses tumor treating fields in combination with other cancer therapies. U.S.-listed shares of Zai gained 31.4%. The companies said they plan to seek premarket approval in the U.S. in the second half of the year. Novocure’s stock is down 2.4% over the past year, while Zai’s shares have declined 37.3%. The S&P 500
SPX,
+0.75%
is down 19.6%.